Zobrazeno 1 - 10
of 342
pro vyhledávání: '"L.Y. Dirix"'
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 2 (2010)
Vast preclinical and clinical evidence has made angiogenesis one of the hallmarks of cancer. In many human tumours, vascular endothelial growth factor (VEGF) has been identified as the crucial mediator of this process. Initial studies suggested that
Externí odkaz:
https://doaj.org/article/538e723cca8c4e658cd0283c5383e4e4
Autor:
K. Van Baelen, H.L. Nguyen, F. Richard, G. Zels, M.M. Karsten, G. Nader Marta, P. Vermeulen, L.Y. Dirix, H. Wuyts, A.D. Dordevic, E. de Azambuja, D. Larsimont, M. Maetens, E. Biganzoli, H. Wildiers, A. Smeets, I. Nevelsteen, P. Neven, G. Floris, C. Desmedt
Publikováno v:
ESMO Open. 8:101276
Autor:
J.M. Bartlett, K. Xu, J. Wong, G. Pond, Y. Zhang, M. Spears, R. Salunga, E. Mallon, K.J. Taylor, A. Hasenburg, C. Markopoulos, L.Y. Dirix, C. Seynaeve, C. van de Velde, D. Rea, C.A. Schnabel, K. Treuner, J. Bayani
Publikováno v:
Annals of Oncology. 33:S602
Autor:
Annette Hasenburg, X Zhang, Arun Seth, Cheryl Crozier, M Larivière, Seth Sadis, Jms Bartlett, Dirk G. Kieback, JM Smith, L.Y. Dirix, Jane Bayani, Mary Anne Quintayo, D.W. Rea, Martin J. Yaffe, Harriet Feilotter, Yutaka Amemiya, C. Markopoulos
Publikováno v:
Cancer Research. 78:P2-09
Large-scale sequencing initiatives have revealed a wealth of common and novel variants as well as copy-number aberrations, across different malignancies. This growing list of variants/aberrations can sometimes be matched to specific therapeutics. Suc
Autor:
Jms Bartlett, L.Y. Dirix, T Piper, Annette Hasenburg, Dirk G. Kieback, Carine Seynaeve, Elizabeth Mallon, Cjh Can de Velde, D.W. Rea, Paul C. Boutros, CQ Yao, Elizabeth N. Kornaga, C. Markopoulos, Jane Bayani
Publikováno v:
Cancer Research. 78:P1-06
Multiparametric assays for risk are increasingly used in the management of node-negative and node-positive hormone receptor-positive invasive breast cancer. Data from multiple sources suggests different tests may provide different risk estimates at t
Autor:
Cjh van de Velde, Carine Seynaeve, L.Y. Dirix, D.W. Rea, Jane Bayani, C. Markopoulos, T Piper, James D. Thomas, Elizabeth Mallon, Annette Hasenburg, Jms Bartlett, Dirk G. Kieback
Publikováno v:
Cancer Research. 78:P1-06
Histological grade remains an independent predictor of outcome for invasive breast cancer. The internationally accepted standard grading system is the Elston and Ellis grading system based on a local hospital (Nottingham) cohort treated between 1951-
Autor:
Quang M. Trinh, Gun Ho Jang, CQ Yao, Melanie Spears, Jms Bartlett, L.Y. Dirix, D.W. Rea, C. Markopoulos, Irina Kalatskaya, Julie Livingstone, Dirk G. Kieback, Elizabeth N. Kornaga, Paul C. Boutros, Lincoln Stein, Cheryl Crozier, Jane Bayani, Annette Hasenburg
Publikováno v:
Cancer Research. 78:PD4-11
Hormone receptor positive breast cancer remains an ongoing therapeutic challenge. Despite optimal anti-endocrine therapies, most breast cancer deaths follow a diagnosis of early luminal cancer. Data describing molecular events in breast cancer has ye
Autor:
Mark M. Kockx, S. Van Laere, Yannick Waumans, C. Rypens, Koen M. Marien, C. Van Berckelaer, C Colpaert, P. van Dam, L.Y. Dirix, Peter B. Vermeulen
Publikováno v:
Cancer Research. 79:P4-06
Introduction The mechanisms contributing to the aggressive biology of inflammatory breast cancer (IBC) are still under investigation. Our lab reported a 79-gene signature that is shaped by specific immune response programs and discriminates between I
Publikováno v:
Cancer Research. 77:P1-06
Background A growing understanding of the molecular biology of cancer and the identification of specific aberrations driving cancer evolution have led to the development of various targeted agents. Tumors can exhibit significant heterogeneity and thi
Autor:
M-C. Liu, Joseph A. Sparano, M.M. Moezi, S-B Kim, Elizabeth Tan-Chiu, Mark Kozloff, V. McNally, L.Y. Dirix, Jung Ho Sohn, B. Simmons, Matthew Wongchenko, José A. García-Sáenz, Marleen Borms, N. Xu, Adam Brufsky, David Miles, Thierry Velu
Publikováno v:
Cancer Research. 77:P4-22
Resistance to standard taxane-based chemotherapy is common in triple-negative breast cancer (TNBC). Mutations and gene amplifications in the MAPK pathway that upregulate MAPK signaling are present in many TNBC tumors. Upregulation of the MAPK signali